To further identify the clinical relevance of our findings, we evaluated the correlation of expression levels between USP9X and EGLN3 in 5 pairs of primary cholangiocarcinoma and matched adjacent noncancerous tissues by immunoblotting. This evidence concerns the gene EGLN3 and cholangiocarcinoma.